Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GALK1 | P51570 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30098456 | 1.00 | KDM4E (0.55) | KDM4EMAPKAPK2LMNACYP3A4CYP2D6 | |
| SCHEMBL30937994 | 0.86 | HASPIN (0.47) | KDM4EMAPKAPK2LMNACYP3A4CYP2D6 | |
| SCHEMBL14893839 | 0.86 | HASPIN (0.47) | KDM4EMAPKAPK2LMNACYP3A4CYP2D6 | |
| SCHEMBL27598089 | 0.85 | KDM4E (0.58) | KDM4EMAPKAPK2LMNACYP3A4CYP2D6 | |
| SCHEMBL14571338 | 0.85 | DGAT2 (0.46) | KDM4EMAPKAPK2MAPTGALK1ATM | |
| SCHEMBL117921 | 0.84 | NR4A1 (0.60) | KDM4EMAPKAPK2LMNACYP3A4CYP2D6 | |
| SCHEMBL29702097 | 0.84 | NR4A1 (0.60) | KDM4EMAPKAPK2LMNACYP3A4CYP2D6 | |
| SCHEMBL4040801 | 0.82 | KDM4E (0.55) | KDM4EMAPKAPK2LMNACYP3A4CYP2D6 | |
| Water SCHEMBL5659378 | 0.82 | NR4A1 (0.58) | KDM4EMAPKAPK2LMNACYP3A4CYP2D6 | |
| SCHEMBL17040876 | 0.82 | KDM4E (0.55) | KDM4EMAPKAPK2LMNACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20220165962-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME | LT MATERIALS CO., LTD. (KR) | 2022-05-26 | — | — | US | disclosed |
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| WO-2020132045-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEUROPROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020081923-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |
| US-8481532-B2 | PDE-10 inhibitors | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481532-B2 | PDE-10 inhibitors | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110178083-A1 | PDE-10 INHIBITORS | ENVIVO PHARMACEUTICALS, INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110178083-A1 | PDE-10 INHIBITORS | ENVIVO PHARMACEUTICALS, INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110178083-A1 | PDE-10 INHIBITORS | ENVIVO PHARMACEUTICALS, INC. | 2011-07-21 | — | — | US | disclosed |
| EP-2318410-A2 | NEW SMALL-MOLECULE PDE-10 INHIBITORS | Envivo Pharmaceuticals, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010006130-A2 | PDE-10 INHIBITORS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010006130-A2 | PDE-10 INHIBITORS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-4396619-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4382932-A | Isoquinolinium substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | SARM1, NNMT, NQO1 | KDM4E 3009/4885MAPKAPK2 1239/4885LMNA 1261/4885 |
| US-20220165962-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME | CRY1, CYP1A1, CYP1B1 | KDM4E 2452/4885MAPKAPK2 3002/4885LMNA 4003/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | KDM4E 2961/4885MAPKAPK2 421/4885LMNA 4183/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | KDM4E 3212/4885MAPKAPK2 449/4885LMNA 1527/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | KDM4E 2961/4885MAPKAPK2 421/4885LMNA 4183/4885 |
| US-20110178083-A1 | PDE-10 INHIBITORS | PDE12, PDE10A, PDE2A | KDM4E 1349/4885MAPKAPK2 1408/4885LMNA 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.